echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Dongyang Pharmaceutical Group 1 new drugs are coming, 8 innovative drugs hit hard

    Dongyang Pharmaceutical Group 1 new drugs are coming, 8 innovative drugs hit hard

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the CDE official website showed that Dongyang Pharmaceutical’s Class 1 new drug HEC88473 injection and Class 2 new drug Lurasidone delayed-release tablets have been approved for clinical use.


    Dongyang Pharmaceutical has recently been approved as a new clinical drug

    Source: CDE official website

    HEC88473 injection is a glucagon-like peptide-1 receptor (GLP-1)/fibroblast growth factor-21 (FGF21) dual agonist.


    This class 1 new drug was first approved for clinical use on April 7, becoming the first GLP-1/FGF21 dual agonist approved for clinical use in China.


    Lurasidone hydrochloride is an atypical antipsychotic with dual effects.


    According to data from Meinenet, since 2021, Dongyang Pharmaceutical has applied for the listing of 2 new drugs, all of which are insulin; 6 new drugs have been applied for clinical trials, of which 3 have been approved for clinical use.


    2021 Dongyang Pharmaceutical's application for listing/clinical new drugs

    Source: Meinenet MED2.


    Among the three approved clinical new drugs, insulin degludec injection is a new and ultra-long-acting insulin analog developed by Novo Nordisk.


    Source: Minet database, CDE official website

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.